Literature DB >> 14708971

New insights into estrogen receptor function in human breast cancer.

Leigh Murphy1, Tracy Cherlet, Anthony Lewis, Yasmin Banu, Peter Watson.   

Abstract

An important new concept associated with estrogen receptor (ER) function in breast cancer is that ER status/ phenotype is multifaceted. In particular, the two full-length, ligand binding ERs (ER-alpha and ER-beta) and possibly multiple variant isoforms of ER must be considered. In addition, cross-talk factors that can influence ER activity in a ligand independent fashion and factors downstream of the ER, including coactivators and corepressors, clearly have important roles in ER function. Their careful evaluation in addition to ER status will be necessary to more fully understand the etiology of breast cancer and the changes occurring in estrogen signaling during breast tumorigenesis and breast cancer progression. Such knowledge is necessary to have a significant impact on better prevention and treatment strategies for human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14708971     DOI: 10.1080/07853890310014579

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  12 in total

1.  Oestrogen receptor beta (ERbeta) polymorphism and its influence on breast cancer risk.

Authors:  D Surekha; K Sailaja; D Nageswara Rao; D Raghunadharao; S Vishnupriya
Journal:  J Genet       Date:  2009-08       Impact factor: 1.166

2.  Progressive increase of glucose transporter-3 (GLUT-3) expression in estrogen-induced breast carcinogenesis.

Authors:  M A Kocdor; H Kocdor; J S Pereira; J E Vanegas; I H Russo; J Russo
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

Review 3.  Estrogen receptor-beta and breast cancer: translating biology into clinical practice.

Authors:  Yuet-Kin Leung; Ming-Tsung Lee; Hung-Ming Lam; Pheruza Tarapore; Shuk-Mei Ho
Journal:  Steroids       Date:  2012-03-29       Impact factor: 2.668

Review 4.  Steroid hormone receptors as prognostic markers in breast cancer.

Authors:  Maggie C Louie; Mary B Sevigny
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

5.  Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.

Authors:  Lisa K Pierson-Mullany; Carol A Lange
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

6.  Effects of lifelong exercise training on mammary tumorigenesis induced by MNU in female Sprague-Dawley rats.

Authors:  Ana I Faustino-Rocha; Adelina Gama; Paula A Oliveira; Antonieta Alvarado; Maria J Neuparth; Rita Ferreira; Mário Ginja
Journal:  Clin Exp Med       Date:  2016-04-19       Impact factor: 3.984

Review 7.  ERbeta in breast cancer--onlooker, passive player, or active protector?

Authors:  Emily M Fox; Rebecca J Davis; Margaret A Shupnik
Journal:  Steroids       Date:  2008-04-20       Impact factor: 2.668

Review 8.  Endocrine resistance in breast cancer--An overview and update.

Authors:  Robert Clarke; John J Tyson; J Michael Dixon
Journal:  Mol Cell Endocrinol       Date:  2015-10-09       Impact factor: 4.102

9.  Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours.

Authors:  G P Skliris; E Leygue; L Curtis-Snell; P H Watson; L C Murphy
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

10.  Estrogen receptor-beta: why may it influence clinical outcome in estrogen receptor-alpha positive breast cancer?

Authors:  Margaret A Shupnik
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.